Novavax To Participate In Oxford University Study Comparing Mixed COVID-19 Vaccine

Novavax Inc. (NVAX) said Thursday that it will participate in a newly expanded Phase 2 clinical trial called "Comparing COVID-19 Vaccine Schedule Combinations - Stage 3" or Com-COV3. The study will be led by the University of Oxford and funded by the UK Vaccines Taskforce or VTF and the National Institute for Health Research or NIHR.

Novavax' recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373, is one of the three COVID-19 vaccines that will be studied in adolescents to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.

The clinical trial will include at least 360 adolescents 12-16 years of age. Volunteers will receive an authorized vaccine as a first dose and then at least 8 weeks later will receive one of three different vaccines as a second dose.

The company noted that all participants will be randomly allocated at the time of the second dose to receive either a full dose or half dose of the same vaccine given for the first dose, a full dose of the Novavax vaccine or a half dose of a different authorized vaccine.

The research will compare the immune system responses from those who receive a heterologous regimen to those who receive a homologous regimen.

Under the protocol, participants will be followed for safety and immune responses. Results from the study are expected within a few months.

The company stated that the UK Medicines and Healthcare products Regulatory Agency and Joint Committee on Vaccination and Immunisation will formally assess the safety and efficacy of any new vaccination process before advising whether it is rolled out.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Merck & Co., Inc., known as MSD outside the U.S. and Canada, has recalled one lot of intravenous antibiotic Cubicin (daptomycin for injection) 500 mg for the potential presence of particulate matter identified as glass particles, the U.S. Food and Drug Administration or FDA said in a statement. The National Restaurant Association or NRA shot out a letter to the U.S. Conference of Mayors suggesting that expanded outdoor dining is the need of the hour for the restaurant industry to sustain the winter. The NRA also warned that thousands of restaurants without this facility could close down very soon. The U.S. Food and Drug Administration is investigating a multistate outbreak of Salmonella Oranienburg infections linked to whole, fresh onions. The outbreak has resulted in 652 illnesses in consumers across the U.S. to date. The traceback investigation has identified Hailey, Idaho -based ProSource Inc., also known as ProSource Produce, LLC, as a source.
Follow RTT